SynAging provides in vitro and in vivo models to test potential symptomatic and diseases modifying therapeutic candidates for their potential benefit in Parkinson’s disease (PD).
SynAging’s models are based on the neurotoxicity of misfolded-α-synuclein-aggregates:
- low number soluble oligomers (aSO), or
- fibrillar preparations α-synuclein (aSF).
Preparations are made in house using a confidential physicochemical protocol, producing highly reproducible results, which is SynAging's specialty. No crossslinkers or helper proteins are used for stabilization. All preparations have long term stability during storage and are validated by quality control, before their application in client projects.
BDNF and EGCG have been validated as positive controls in SynAging’s in vitro model. Test items can be investigated and optimized in our highly reproducible in vitro assays.
SynAging's has two in vivo PD models:
(i) α-synuclein oligomer (aSO) based, showing first cognitive imparement within 15 days in mice, reduction of synaptic markers, dopaminergic markers, and neuroinflammation. Mice injected with αSO and challenged with amphetamine displayed an anticlockwise circling behaviour, typical for dopaminergic neuron deficit and relevant for movement disorders of Parkinson’s disease. And alternatively:
(ii) sonicated α-synuclein fibril (aSF) based, showing so called 'spreading' within 15 days and cognitive impairment after 90 days.
Both models are induced by a single intra-striatal injection of a small amount of aggregate into the right striatum of WT mice.
Putative PD therapeutics are tested for their capabilities to ameliorate the symptoms, or revert the neurodegeneration in SynAging's models. So far, no public positive control for in vivo models has been identified world wide.
General neurodegeneration models using various stimuli, such as excitotoxicity and oxidative stress can be used to further characterize the effect of test items.
Please see: Parkinson´s_Disease in Science and Technology